Expression and methylation status of MMR and MGMT in well-differentiated pancreatic neuroendocrine tumors and potential clinical applications
- 16 June 2022
- journal article
- research article
- Published by Springer Nature in Endocrine
- Vol. 77 (3) , 538-545
Abstract
Purpose Recent studies claim that immune checkpoint inhibitors are effective in defective mismatch repair (dMMR) cancers. This raises the question of whether similar therapies are effective in PanNETs (pancreatic neuroendocrine tumors); however, in general, assessment of MMR status in PanNETs has been inconsistent in previous studies. MGMT (O6-methylguanine-DNA methyltransferase) is potentially important for guiding temozolomide (TMZ) therapy in glioblastoma. The number of reports on MGMT expression and promoter methylation in PanNETs are limited. Methods In this study we assessed the expression of MGMT and MMR proteins MSH2, MSH6, MLH1 and PMS2 in a series of PanNETs by IHC. The methylation status of MGMT and MMR genes in a subset of PanNETs was further assessed by MS-MLPA analysis. Survival curves were constructed using the Kaplan-Meier method, and differences were assessed using the log-rank test. Multivariate Cox proportional hazards regression models were used to determine the prognostic value of the variables. Results According to evaluation criteria for mismatch repair defects, none of PanNETs shown nuclear staining loss for MSH2, MSH6, MLH1, and PMS2. MGMT low-intensity PanNETs were more commonly found in higher grade, higher Ki67 index and non-functional tumors (P < 0.05). In multivariate analysis, stage III–IV and low-intensity MGMT were shown to be independent risk factors for progression of PanNETs in the entire cohort, non-functioning subgroup and G2 subgroup (P < 0.05 for all). MGMT promoter methylation tended to be higher in the group with low expression of MGMT, However, methylation of MGMT did not statistically correlate with low expression of MGMT (P = 0.153). Conclusions In conclusion, our study suggests that decreased expression of MGMT but not MMR is associated with a higher risk of progression of pancreatic neuroendocrine tumors.Keywords
Funding Information
- Chinese Academy of Medical Sciences Initiative for Innovative Medicine (2016-I2M-1-001, 2016-I2M-1-001, 2016-I2M-1-001, 2016-I2M-1-001, 2016-I2M-1-001)
- National Natural Science Foundation of China (81672648)
- CAMS Central Public Welfare Scientific Research Institute Basal Research Expenses (2016ZX310176-4)
This publication has 29 references indexed in Scilit:
- Molecular Markers for Novel Therapeutic Strategies in Pancreatic Endocrine TumorsPancreas, 2013
- Loss of Expression of DNA Mismatch Repair Proteins Is Rare in Pancreatic and Small Intestinal Neuroendocrine TumorsArchives of Pathology & Laboratory Medicine, 2011
- Tailored temozolomide therapy according to MGMT methylation status for elderly patients with acute myeloid leukemiaAmerican Journal of Hematology, 2011
- Selection of Endometrial Carcinomas for DNA Mismatch Repair Protein Immunohistochemistry Using Patient Age and Tumor Morphology Enhances Detection of Mismatch Repair AbnormalitiesAmerican Journal of Surgical Pathology, 2009
- O 6-Methylguanine DNA Methyltransferase Deficiency and Response to Temozolomide-Based Therapy in Patients with Neuroendocrine TumorsClinical Cancer Research, 2008
- Analysis of molecular pathways in sporadic neuroendocrine tumors of the gastro‐entero‐pancreatic systemInternational Journal of Cancer, 2007
- Prognostic Significance of O6-Methylguanine-DNA Methyltransferase Determined by Promoter Hypermethylation and Immunohistochemical Expression in Anaplastic GliomasClinical Cancer Research, 2005
- Aberrant Hypermethylation of Tumor Suppressor Genes in Pancreatic Endocrine NeoplasmsAnnals of Surgery, 2003
- CpG island methylation in carcinoid and pancreatic endocrine tumorsOncogene, 2003
- Cancer as an epigenetic disease: DNA methylation and chromatin alterations in human tumoursThe Journal of Pathology, 2001